» Articles » PMID: 18825311

Endogenous Estrogen Exposure in Relation to Distribution of Histological Type and Estrogen Receptors in Gastric Adenocarcinoma

Overview
Journal Gastric Cancer
Date 2008 Oct 1
PMID 18825311
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Estrogen might protect women against gastric adenocarcinoma of the intestinal histological type. We addressed this hypothesis and proposed that gastric estrogen receptors (ERs) are involved.

Methods: A population-based cohort of patients with gastric adenocarcinoma diagnosed in 1958-2004 in the county of Stockholm was identified through the Swedish Cancer Register. The patients were categorized regarding their endogenous estrogen exposure at diagnosis into: women aged less than 50 years, labelled "exposed women" (n=364), men aged less than 50 years, labelled "unexposed men" (n=396), and women aged more than 70 years, labelled "unexposed women" (n=3008). Tumor specimens were reviewed, and 289 cases were classified into intestinal (n=101) or diffuse type (n=188). Cases of intestinal adenocarcinomas (n=45) were tested for presence of ERalpha, ERbeta, and ERbeta cx by immunohistochemistry.

Results: Compared to "exposed women", the intestinal type of gastric adenocarcinoma was more than four times more common among "unexposed men" (odds ratio [OR], 4.7; 95% confidence interval [CI], 2.2-10.3) and nine times more common among "unexposed women" (OR, 9.1; 95% CI, 4.3-19.6). No differences in ER expression were found. A comparison of ERs in tissues taken from the tumors and adjacent gastric mucosa revealed a loss of ERbeta and a gain of ERalpha in the tumor cells. The presence of ERbeta cx was identified for the first time in gastric tumors.

Conclusion: Gastric adenocarcinoma of the intestinal type is less common in women with high endogenous estrogen exposure, indicating a preventive effect of estrogen. No differences in the distribution of ERs was found between the three estrogen exposure groups. The presence of ERbeta cx in gastric cancer warrants further investigation.

Citing Articles

Global, regional, and national burden of early-onset gastric cancer.

Tan N, Wu H, Cao M, Yang F, Yan X, He S Cancer Biol Med. 2024; 21(8).

PMID: 39109684 PMC: 11359495. DOI: 10.20892/j.issn.2095-3941.2024.0159.


Sex Disparity in Patients with Gastric Cancer: A Systematic Review and Meta-Analysis.

Luan X, Niu P, Wang W, Zhao L, Zhang X, Zhao D J Oncol. 2022; 2022:1269435.

PMID: 36385957 PMC: 9646304. DOI: 10.1155/2022/1269435.


Gene Regulatory Network Characterization of Gastric Cancer's Histological Subtypes: Distinctive Biological and Clinically Relevant Master Regulators.

Russi S, Marano L, Laurino S, Calice G, Scala D, Marino G Cancers (Basel). 2022; 14(19).

PMID: 36230884 PMC: 9563962. DOI: 10.3390/cancers14194961.


Clinicopathologic Characteristics of Young Gastric Cancer Patients: Diagnostic Staging Accuracy and Survival.

Kim W, Youn S, Won Y, Min S, Park Y, Ahn S J Minim Invasive Surg. 2022; 23(4):163-171.

PMID: 35601641 PMC: 8985612. DOI: 10.7602/jmis.2020.23.4.163.


Estrogen Aggravates Tumor Growth in a Diffuse Gastric Cancer Xenograft Model.

Lee S, Kim K, Lee S, Jung J Pathol Oncol Res. 2021; 27:622733.

PMID: 34257587 PMC: 8262185. DOI: 10.3389/pore.2021.622733.


References
1.
Heuch I, Kvale G . Menstrual and reproductive factors and risk of gastric cancer: a Norwegian cohort study. Cancer Causes Control. 2000; 11(9):869-74. DOI: 10.1023/a:1008975817061. View

2.
Tokunaga A, Kojima N, Andoh T, Matsukura N, Yoshiyasu M, Tanaka N . Hormone receptors in gastric cancer. Eur J Cancer Clin Oncol. 1983; 19(5):687-9. DOI: 10.1016/0277-5379(83)90186-4. View

3.
Ekstrom A, Eriksson M, Hansson L, Lindgren A, Signorello L, Nyren O . Occupational exposures and risk of gastric cancer in a population-based case-control study. Cancer Res. 1999; 59(23):5932-7. View

4.
Lindblad M, Garcia Rodriguez L, Chandanos E, Lagergren J . Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer. 2006; 94(1):136-41. PMC: 2361087. DOI: 10.1038/sj.bjc.6602906. View

5.
Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C . Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer. 2003; 105(3):408-12. DOI: 10.1002/ijc.11083. View